Autopsy report · NCT00544674
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
Cause of deathOther
“Terminated early due to discovery of new mechanism of activation.”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 1 year 5 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 2 years 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Proacta, Incorporated
- Sponsor type
- Industry
- Conditions
- Lung Cancer
- Interventions
- PR104; F-18-fluoromisonidazole
- Participants
- 5
- Sites
- 18
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.